Compound A HCl/HBr Solid-State Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymorphic forms of Compound A, a selective inhibitor of C5aR, do not adequately address the solubility, stability, and efficacy issues necessary for effective treatment of inflammatory and autoimmune diseases mediated by C5aR, such as ANCA-associated vasculitis, complement 3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.
Innovation Solution
Development of new salt forms of Compound A, including crystalline and amorphous forms, particularly HCl and HBr salts, which enhance solubility, stability, and therapeutic efficacy by providing formulations suitable for treating diseases mediated by C5aR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing polymorphic forms of Compound A are used, then the compound can be administered for treating C5aR-mediated diseases, but the solubility, stability, and efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by creating new salt forms (HCl and HBr salts) of Compound A with different crystalline and amorphous polymorphic forms. These parameter changes in chemical composition and physical state enable improved solubility, stability, and therapeutic efficacy while maintaining reliability for treating C5aR-mediated diseases.
Solution Approach 2:
The patent employs composite materials by combining Compound A with different counterions (HCl, HBr) and solvent molecules to create various salt forms and solvates. These composite structures exhibit enhanced physical and chemical properties including improved solubility, stability, and bioavailability while maintaining therapeutic effectiveness.
2Stability of the object's composition
If new salt forms including crystalline and amorphous forms are developed, then solubility and stability are enhanced, but formulation complexity increases
Solution Approach 1:
The patent uses parameter changes to create distinct crystalline and amorphous forms along with different salt forms (HCl, HBr) and solvates. By controlling physical and chemical parameters during formulation, the patent achieves enhanced stability and solubility while managing formulation complexity through systematic classification of forms.
3Reliability
If multiple polymorphic forms are discovered and developed, then solubility and efficacy improve, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically exploring different salt forms, crystalline structures, and amorphous forms of Compound A. By controlling crystallization conditions, pH, and other parameters during manufacturing, the patent achieves improved efficacy and solubility while managing manufacturing complexity through established formulation techniques.
Data Source
AI summary
The present disclosure provides crystalline and amorphous HCl and HBr salt forms of (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, pharmaceutical compositions, and methods of treating a disease mediated by C5aR inhibition.